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ABSTRACT 25 
ChREBP is an essential transcription factor for lipogenesis. Its physiological role in 26 
adipose tissue has been little studied and the control of its expression remains unknown 27 
in human adipocytes. We have studied ChREBP mRNA and protein expression levels 28 
in the liver and the omental (OM) and subcutaneous (SC) adipose tissues from obese 29 
and lean subjects, as well as in human differentiated preadipocytes. Liver and OM and 30 
SC adipose tissues biopsies were obtained from lean and obese patients. Human 31 
preadipocytes were isolated from the adipose tissues from obese patients and 32 
differentiated under adipogenic conditions. ChREBP expression levels were quantified 33 
by RT-PCR and Western blot analysis. We found opposite ChREBP regulation in the 34 
liver and adipose samples. ChREBP increased in the liver from obese compared to lean 35 
subjects, whereas the expression decreased in both adipose tissues. The mRNAs of 36 
other adipogenic markers were checked in these tissues. The pattern of FASN was 37 
similar to the one for ChREBP, ADCY3 decreased in both adipose tissues from obese 38 
patients, AP2 was only decreased in OM adipose tissue of obese patients and ATGL did 39 
not change. The levels of ChREBP mRNA and protein showed dramatic increases 40 
during the differentiation of human OM and SC preadipocytes. In conclusion, ChREBP 41 
expression has an opposite regulation in the liver and adipose tissue from obese subjects 42 
which is compatible with the increased hepatic lipogenesis and decreased adipocytic 43 
lipogenesis found in these patients. The dramatic increase of ChREBP mRNA and 44 
protein levels during preadipocytes differentiation suggests a role in adipogenesis. 45 
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1. INTRODUCTION 50 
Dysregulation of the synthesis of fatty acids (lipogenesis) contributes to metabolic 51 
disease such as obesity, hepatic steatosis, diabetes and cardiovascular diseases [1].  52 
Liver and adipose tissue are the main organs where lipogenesis takes place, glucose 53 
being the primary source of carbons for fat biosynthesis. Triglycerides (TG) are 54 
synthesized from fatty acids and glycerol; in the liver, TG can be packaged into VLDL 55 
and secreted into the circulation, stored as lipid droplets or they can enter the beta-56 
oxidation pathway. In the adipose tissue, TG are mainly stored, thus being a major 57 
source of energy. In both tissues lipogenesis is controlled by hormonal and nutritional 58 
signals (insulin and glucose). Insulin secreted in response to elevated blood glucose 59 
levels, is well known to increase transcription of lipogenic genes mediated by the 60 
transcription factor SREBP-1 in liver [2]. However, the mechanism that activates the 61 
glucose signaling pathway by an excess of carbohydrates was not well known until the 62 
discovery of the transcription factor Carbohydrate Responsive element-binding protein 63 
(ChREBP). ChREBP activation by glucose induces the gene expression of most 64 
enzymes involved in lipogenesis [3] as well as the liver pyruvate kinase, an essential 65 
regulator of glycolysis. Other target genes of ChREBP are involved in the NADPH 66 
supply system and gluconeogenesis [4]. 67 
Despite the extensive knowledge gained in recent years regarding the role of ChREBP 68 
in the liver, its physiological role in adipose tissue has been barely studied and the 69 
control of its expression remains unknown in adipocytes. Moreover, most of the 70 
questions regarding ChREBP regulation have been always addressed in rodent models 71 
but not in human samples. To our knowledge, this is the first study involving different 72 
human tissues, such as liver and two adipose tissue depots. We have found that the 73 
regulation of ChREBP expression in differentiated preadipocytes increases in agreement 74 
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with rodent models, but there is a dysregulation in the adipose tissue of obese patients 75 
compared to lean patients, characterized by a decrease in ChREBP and FASN mRNAs, 76 
which is in contrast with the increase of the expression of these genes observed in the 77 
liver from obese versus lean patients. 78 
2. MATERIALS AND METHODS 79 
2.1. Subjects, tissue samples and cell cultures. 80 
Patients were classified as obese or lean according to their body mass index (BMI), 81 
following the World Health Organization criteria, BMI ≥30 and <25 kg/m2, 82 
respectively. Surgeries were performed at the Hospital Universitario La Paz (Madrid) 83 
and the Hospital Clínico Universitario S. Carlos (Madrid). Informed written consent 84 
was obtained from all the patients. 85 
The protocols were approved by the Ethical Committees of all the institutions involved 86 
following the principles of the Declaration of Helsinki.  87 
For expression analysis experiments in whole tissues, human adipose tissue from two 88 
locations, omental (OM) and subcutaneous (SC), were obtained from 24 obese patients 89 
undergoing bariatric surgery and from 11 lean patients who presented hiatus hernia, 90 
gastroesophageal reflux or esophageal achalasia. In addition, human liver was obtained 91 
from 9 out of the above obese patients and from 4 lean patients with esophageal 92 
achalasia. 93 
For experiments conducted in primary cultures of OM and SC preadipocytes, human 94 
adipose tissue from both regions was obtained from 8 additional obese patients, under 95 
the above ethical considerations. Precursors cells were isolated and differentiated under 96 
defined adipogenic conditions as previously shown [5]. Differentiated preadipocytes 97 
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were harvested at 0, 3, 6 and 12 days. (mRNA, n=3 from each depot). Additionally, 98 
mature floating adipocytes were separated from the stromal-vascular cells (SVC) from 99 
adipose tissue of obese patients. 100 
To investigate the influence of insulin on ChREBP mRNA expression, after a 101 
differentiation period of 10 days, cells were treated for 48 additional hours with 10% 102 
depleted newborn calf serum, and treated or not with 100 mM insulin during the last 24 103 
h. Cells were then harvested at day 12. Depleted serum was obtained as previously 104 
described [6] and showed undetectable levels of insulin as measured by RIA. 105 
2.2. RNA extraction and quantitative Taqman RT-PCR 106 
RNA of tissue samples and differentiated preadipocytes was extracted with the 107 
RNeasy lipid tissue kit (Quiagen, Madrid, Spain) following the manufacturer´s 108 
protocol. Integrity and concentration of RNA were checked with the Bioanalyzer 109 
2100 (Agilent Technologies, Santa Clara, CA). cDNA from 1 µg of each RNA 110 
sample was synthesized using iScript cDNA Synthesis Kit (BioRad, Hercules, CA) 111 
according to the kit instructions. The expression levels of ChREBP, FASN, ATGL, 112 
ADCY3, AP2 and PPARG mRNAs were analyzed by RT-PCR using predesigned 113 
Taqman Assays probes (Applied Biosystems, Foster City, CA) on a 7300 Real-time 114 
PCR System (Applied Biosystems, Foster City, CA). Data were referred to IPO8 as 115 
endogenous control gene, as we have recently reported IPO8 as an outstanding gene 116 
for normalization of gene expression studies in human adipose tissue and 117 
differentiated preadipocytes in primary cultures [7]. Liver samples were also referred 118 
to IPO8, after checking in some experiments that the results obtained with IPO8 119 
were similar to those obtained using other endogenous controls such as 18S and 120 
cyclophilin (PPIA)(not shown). 121 
 6 
2.3. Western-blots 122 
Total protein extracts were obtained from tissues and cells using standard protocols. 123 
Seventy-five µg of each sample were resolved by SDS-PAGE and transferred to 124 
nitrocellulose membranes (PROTRAN, Whatman Inc, Florham Park, NJ) in a buffer 125 
containing 25mM Tris, 200 mM glycine and 20% methanol. After blocking the 126 
membrane with 5% low-fat dried milk in Tris-buffered saline containing 0.05% Tween-127 
20, the levels of ChREBP protein were detected using a 1:500 dilution of the specific 128 
antibody (sc-21189, Santa Cruz Biotechnology, Santa Cruz, CA), followed by a 1:7500 129 
dilution of IRDye 800CW donkey anti-goat IgG (LI-COR Biosciences, Lincoln, NE). 130 
Beta-actin antibody (sc-47778, Santa Cruz Biotechnology, Santa Cruz, CA) was used as 131 
a loading control followed by incubation with IRDye 800 anti-mouse IgG (LI-COR, 132 
Lincoln, NE). All immunoreactive fluorescent bands were visualized on  the Odyssey 133 
Infrared Imaging System (LI-COR Biosciences, Lincoln, NE) and quantified by ImageJ 134 
1.410 (http://rsb.info.nih.gov/ij) 135 
2.4. Statistical analysis 136 
Results of mRNA expression among groups are shown as fold-changes which were 137 
calculated by the 2
- Ct
 method. Other data are means  SEM. Statistically significant 138 
differences between two groups were determined by the Student t-test (P< 0.05). Due to 139 
the low sample size in some groups, significant differences were confirmed and 140 
evaluated with power analysis, using G*Power 3 software and using a minimal 141 
detectable significant power of 0.80 [8]. 142 
Correlation analysis was determined by Pearson´s correlation coefficient test (r). Data 143 
from the differentiation experiments (4 groups) were submitted to ANOVA analysis, 144 
after testing for homogeneity of variance by Bartlett´s test. Statistically significant 145 
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differences were identified  by the least significant difference method.  146 
3. RESULTS 147 
3.1. Biochemical profile of the patients. 148 
The biochemical parameters of the different patients included in this study are shown 149 
in Table 1. No significant differences were observed in the age of the patients among 150 
groups. As expected, BMIs from the obese groups were higher than those from their 151 
respective leans. No changes were observed in basal glucose, triglycerides or total 152 
cholesterol in plasma, between lean and obese patients used for the study of the liver. 153 
Regarding the lean and obese subjects used for the study of the adipose tissue 154 
samples, although glycemia and triglyceridemia were significantly increased (P < 155 
0.05) in the obese groups compared to the lean patients, the variables were within 156 
normal ranges. 157 
Liver biopsies from all the obese subjects showed mild (n=3) to moderate fat 158 
accumulation (steatosis) (n=6), with no inflammation signs observed. Grading of 159 
histological lesions was determined as described [9] Although fat infiltration was not 160 
studied in the hepatic samples from the lean patients, we compared alanine 161 
aminotransferase (ALT) levels in both lean and obese groups being 27.8  1.9 and 162 
44.3  7.6, respectively (p< 0.05). Serum ALT levels are correlated to liver fat [10] 163 
and are a good predictor of hepatic steatosis [11]. 164 
3.2. ChREBP expression in liver and in omental and subcutaneous adipose tissues 165 
from lean and obese subjects. 166 
The ChREBP mRNA expression was studied in the liver and the OM and SC adipose 167 
tissues from lean and obese individuals. As shown in Figure 1A, opposite regulation 168 
was found in the liver and adipose samples: the expression in the liver from obese 169 
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patients doubled that one of the leans, whereas in both adipose tissues, the expression 170 
was decreased significantly by 50% or more (in OM). In order to compare  the 171 
expression level among tissues from lean individuals, ChREBP mRNA was referred to 172 
the liver which showed the higher levels. Although changes were not significant, the 173 
mean expression of the transcript in the SC adipose tissue from lean individuals 174 
decreased about 15% from that of the liver, whereas the one from the OM depot was 175 
even lower as this depot presented levels of ChREBP mRNA which were two thirds of 176 
the hepatic levels (Figure 1B). To assess the influence of the stromal vascular cells 177 
(SVC) on ChREBP expression, OM and SC adipose tissues from obese subjects were 178 
separated into mature floating adipocytes and SVC. ChREBP expression in SVC 179 
represented only 4 and 13% of the expression in OM and SC floating adipocytes, 180 
expressed as 100%, respectively (Figure 2). 181 
To investigate the protein levels, tissue protein extracts were obtained and western-blots 182 
performed. Figure 3A shows a representative western-blot using liver samples from 183 
obese and lean subjects, and a positive control from human HepG2 cells. As shown, the 184 
levels of ChREBP protein were higher and clearly detected in the livers from obese 185 
individuals as compared to those from the lean, which could be hardly detected. When 186 
the  levels were quantified and normalized to the beta-actin levels, ChREBP protein in 187 
the obese group increased about 3 times over the levels in the lean group (Figure 3B). 188 
The expression in the hepatic samples was further confirmed by correlation analysis: 189 
Relative ChREBP mRNA  expression significantly correlated with ChREBP protein 190 
levels (r= 0.84, p< 0.01). 191 
Though we tried doing western-blots with adipose tissue samples from both depots, no 192 
signal was detected even when increasing  total amounts of protein up to 150 µg, 193 
suggesting that ChREBP protein levels mighy reflect the relative amounts of ChREBP 194 
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mRNA among the different tissues, liver being the tissue with the highest levels of  both 195 
mRNA and protein. Non detectable bands could be also due to dilution of ChREBP 196 
protein in adipocytes with other predominant cells (SVC) whose expression is not as 197 
high as in adipocytes.  198 
We then performed correlation analysis of the ChREBP mRNA levels in OM and SC 199 
adipose depots as well as in liver with the biochemical parameters of the patients 200 
included in the study (BMI, glucose, cholesterol and triglycerides). Only the expression 201 
levels in the OM location, the most affected one with higher difference between groups, 202 
presented a significant correlation with the BMI of the patients (Figure 4). 203 
3.3. FASN, AP2 and ATGL mRNA expression in liver and in OM and SC adipose 204 
tissues from lean and obese subjects. 205 
As an opposite regulation of ChREBP mRNA expression was found in liver and adipose 206 
tissues, other markers involved in adipogenesis were checked in these tissues. Thus, the 207 
FASN mRNA, a marker of lipogenesis, was checked in the three tissues. As shown in 208 
Figure 5A, the pattern was very similar to the one for ChREBP: obesity doubled hepatic 209 
FASN mRNA levels, while decreased them to one third in both OM and SC adipose 210 
tissues. 211 
The transcripts of AP2, a key mediator of intracelular transport of fatty acids, were also 212 
determined and shown in Figure 5B. Although no changes were observed in liver and 213 
SC adipose tissue from lean and obese subjects, a significant decrease was seen in OM 214 
adipose tissue from obese patients. 215 
When mRNA levels of ATGL, a main lipase involved in lipolysis, were measured, no 216 
changes were observed in any of the tissues between lean and obese patients (Figure 217 
5C). Adenylyl cyclases (ADCY) are enzymes involved inthe first steps of lipolysis. 218 
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ADCY3 mRNA levels were measured and are shown in Figure 5D. While the hepatic 219 
levels did not change with obesity, the expression in both OM and SC adipose depots 220 
were decreased in the obese group. 221 
3.4. ChREBP expression during differentiation of preadipocytes.  222 
To further investigate the role of ChREBP in the adipocyte development in humans, we 223 
isolated precursors cells from both OM and SC adipose depots from obese patients. 224 
These primary cultures of preadipocytes were differentiated to adipocytes in the 225 
presence of 100 nM insulin and harvested at different days (0, 3, 6 and 12 days). 226 
Adipocyte differentiation was checked by visual inspection of the accumulated lipids in 227 
the cells and by analyzing the expression of well known markers of adipocytic 228 
differentiation such as PPARG and AP2 , which increased as expected  through 229 
adipogenesis (Figure 6, panels A and B). The levels of expression of  ChREBP mRNA 230 
showed  dramatic increases at all days tested in both OM and SC locations. The pattern 231 
was similar in both depots, as the relative fold-change increased at day 3 and reached 232 
the maximal levels at days 6 - 12 of differentiation (Figure 6, panel C). Protein extracts 233 
were isolated from the differentiated preadipocytes and the levels of CHREBP protein 234 
were measured by Western blots showing increases at all days when compared to day 0 235 
of differentiation (Figure 6, panel D). When the differentiation of the cells was 236 
performed in the absence of insulin during the last 2 days, a dramatic decrease was 237 
observed in ChREBP, AP2 and PPARG mRNA expression (not shown), confirming the 238 
positive role of insulin on their expression in human adipocytes.  239 
 240 
4. DISCUSSION 241 
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ChREBP is a transcription factor with a critical role in the induction of glycolytic and 242 
lipogenic genes by glucose, by means of its binding to the ChREs present in the 243 
promoters of those target genes which are present, among other tissues, in both liver and 244 
WAT.  Though there are studies regarding  the ChREBP physiological function and 245 
activity, very few have been focused in the transcriptional regulation of the gene. 246 
Moreover, most of them have been performed in mammals others than humans [12-14] 247 
and studied almost exclusively the liver. Inactivation of ChREBP causes a complex 248 
phenotype which can not be atributed only to changes in the liver, as this protein is 249 
expressed in other important tissues. To our knowledge this is the first study describing 250 
ChREBP regulation on human liver in vivo and human differentiated preadipocytes 251 
from samples of obese subjects. 252 
Regarding adipocytes in vitro, ChREBP mRNA expression increased dramatically 253 
during the differentiation process of human preadipocytes in culture. Our findings using 254 
human preadipocytes are in agreement with the increased ChREBP mRNA, obtained 255 
during differentiation of murine 3T3 L1 preadipocytes [15]. The CHREBP protein 256 
levels were also increased in our samples. As other important transcription factors 257 
which control adipocyte differentiation and are regulated by insulin and nutrients, 258 
ChREBP is also regulated by insulin in 3T3L1 preadipocytes [15]. Our results show that 259 
during human preadipocytes differentiation, the ChREBP transcripts were clearly down-260 
regulated in the absence of insulin during the last 48 hr. Such changes suggest that the 261 
regulation of ChREBP mRNA in human differentiated preadipocytes is highly sensitive 262 
to the presence of insulin, similarly to the results obtained in other models such as 263 
3T3L1 which are responsive to insulin stimulation [15].  264 
The protein and mRNA ChREBP levels tended to be higher in liver than in adipose 265 
tissues of lean individuals, in agreement with previous results in rats [15, 16]. In fact, 266 
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the protein levels were only detected in the liver but not in the adipose tissues. 267 
However, ChREBP protein was clearly detectable in differentiated preadipocytes in 268 
contrast to the whole tissue suggesting a "dilution" effect. In this line, the ChREBP 269 
mRNA in SVC cells represented only about 5 and 10% of the one present in mature 270 
adipocytes, from OM and SC depots, respectively, suggesting that ChREBP expression 271 
is mainly due to adipocytes.  272 
When comparing lean and obese patients, opposite regulation was found in liver and 273 
adipose tissue. While hepatic ChREBP expression increased in obesity, a decrease was 274 
observed in both adipose tissues, being the OM location more affected. This result 275 
confirms the study by Letexier and coworkers [17] 276 
As stated above, a possible limitation of this kind of studies is the inherent complexity 277 
of the tissues studied in terms of the differences in regulation among cell-types present. 278 
In this regard, adipocytes can represent 70% of the total adipose mass, but only 25% of 279 
the cellular population. The other 75% of the cells of the adipose tissue are fibroblasts, 280 
macrophagues, blood cells, endothelial cells and preadipocytes [18]; although SVC 281 
present low expression of ChREBP mRNA compared to mature adipocytes, we can not 282 
exclude this limitation, as we could only measure the transcripts in samples from obese 283 
patients but not in those of lean individuals. In contrast to adipocytes, the hepatocytes 284 
are the predominant cells (60% of the total number ) of the liver and perform the 285 
majority of its functions [19]. Between SC and OM adipose tissues, there are also 286 
morphological and functional differences and, in addition, specifically OM fat (and 287 
visceral fat, in general) is clearly associated to increased risks to develop obesity-288 
associated disorders such as metabolic syndrome and insulin resistance. Likely the 289 
reduction in the expression of ChREBP in adipose tissue in obesity reflects down-290 
regulation of the pathway leading to lipogenesis to prevent further fat accumulation and 291 
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weight gain.  Curiously, in our study only the ChREBP mRNA expression in the OM 292 
adipose tissue, but not the one in liver or SC fat, was negatively correlated to the 293 
increasing BMI of the patients. This is in contrast to literature which shows that visceral 294 
fat pads were reduced in the ChREBP deficient mice [12] and in a similar way, 295 
ChREBP inhibition in ob/ob mice reduced considerably the weight of white adipose 296 
tissue [14]. This lack of correlation might be due to differences among species. Recent 297 
reports of species- specificity have been published for another gene, PNPLA3, which is 298 
associated to fatty liver in humans but not in mice [20]. It has been shown that a high 299 
BMI is associated with liver steatosis and that the severity of the steatosis decreases 300 
after weight loss [21] and moreover, visceral fat rather than SC fat is a good predictor 301 
for the presence of fatty liver [22] due to its contribution through the portal vein. At this 302 
respect, several studies in humans and rodents have suggested that ChREBP expression 303 
is associated with the excesive accumulation of triglycerides observed in hepatic 304 
steatosis [14] which can be caused by an augmented lipogenesis.  In fact, all liver 305 
samples from the obese subjects in our study show mild to moderate fat infiltration.  306 
In murine hepatocytes it has been shown that ChREBP binds to the ChRE of lipogenic 307 
genes promoters like FASN and ACC [23]. As expected in our study, the opposite 308 
regulation observed in liver and adipose tissue of the ChREBP mRNA was paralleled 309 
by a similar pattern in the lipogenic enzyme FASN. In lean healthy humans, adipose
 310 
tissue lipogenesis, although active, is less responsive than hepatic lipogenesis to acute
 
or 311 
prolonged carbohydrate overfeeding [24]. Similar results have been shown in human 312 
obesity: there is an enhanced hepatic lipogenesis but no evidence for an increased 313 
lipogenic capacity of SC adipose tissue in obese subjects [25]. Our study confirms those 314 
results and further shows that this occurs not only in adipose tissue from SC origin but 315 
also from visceral localization. Although we do not know the exact mechanism of this 316 
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opposite regulation, it could be due to a different tissue specific regulation. It has been 317 
recently described that O-linked -N-acetylglucosamine (O-GlcNAcylation)  is a novel 318 
mechanism increasing ChREBP activity in the liver [26], but there are no reports on 319 
adipose tissue. Alternatively, the regulation of the lipogenic enzymes promoters by 320 
ChREBP could be different in liver and adipose tissue. That is the case for SREBP-1c, a 321 
well established transcription factor which regulates FASN in hepatocytes. Despite the 322 
activation process of SREBP-1c is intact in adipocytes, it does not bind to the functional 323 
SRE/E-box site on the FASN promoter  in adipocytes [27]. This opposite regulation 324 
might have arisen as a consequence of the adipose tissue expansion limit, which once 325 
reached, will reduce the capacity of the adipose tissue to store energy efficiently, and 326 
lipids begin to accumulate in other tissues such as the liver, contributing to lipotoxicity 327 
and associated pathologies (insulin resistance, diabetes or fatty liver) [28]. In a recent 328 
study with adipose tissues from obese subjects we found a generalized decrease in the 329 
expression of enzymes involved in lipogenesis, as well as in lipolysis, [29], both likely 330 
due to a defense mechanism. Regarding lipolysis, the mRNA expression of two 331 
enzymes, ADCY3 and ATGL, were assayed in the liver and adipose tissues samples of 332 
our present study. No changes were observed in the tissue expression levels of ATGL 333 
between lean and obese subjects, however, ADCY3 expression decreased in adipose 334 
tissue of OM and SC origin, while no differences were seen in the liver. These data are 335 
in agreement with previous results, as ATGL mRNA levels were found to be unaffected 336 
in obesity [30] [31] and four isoforms of ADCY, ADCY3 included, were decreased in 337 
adipose tissue of obese subjects [29]. Adipocytes release fatty acids into the circulation 338 
when nutrients are needed but a state of obesity would not be a situation in which 339 
energy expenditure is required. Thus, lipolysis in these tissues of obese patients could 340 
be inhibited to avoid a higher excess of free fatty acids. Among fatty acids, 341 
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polyunsaturated fatty acids (PUFA) are potent inhibitors of lipogenesis by 342 
downregulating ChREBP gene expression [32]. In situations in which lipolysis is high, 343 
there is a selective mobilization of polyunsaturated fatty acids (PUFA) to circulation 344 
[33], if lipolysis were inhibited in some way, mobilization of PUFA would be also 345 
decreased resulting in accumulation inside the adipocytes. This might be happening in 346 
the adipose tissue of the obese patients of our study, and this putative increase in 347 
adipose tissue PUFA could be suppressing lipogenic enzymes by inhibiting ChREBP 348 
expression. In addition, a decrease of AP2 could reduce NEFA release, in that case in 349 
absence of AP2, lipolysis would decrease and the NEFA (and concomitantly PUFA) 350 
content inside the adipocyte could increase up to 3-fold [34] .  351 
On the other hand, hepatic PUFA are clearly decreased in the liver of obese patients 352 
with steatosis [35], and this decrease might account for the higher levels of hepatic 353 
ChREBP mRNA, as the inhibition by PUFA could be abolished.  354 
In conclusion, the present study shows for the first time data on the regulation of 355 
ChREBP expression in human differentiated preadipocytes and an opposite regulation 356 
of its expression in the liver and adipose tissue from obese subjects. These results are 357 
compatible with a limited lipogenic/adipogenic capacity in adipocytes which might lead 358 
to spillover of lipids excess to other tissues such as the liver with an increased 359 
lipogenesis contributing to lipotoxicity and comorbilities found in obese patients.  360 
 361 
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FIGURE LEGENDS. 367 
Figure 1. ChREBP mRNA in liver, omental and subcutaneous adipose tissue from 368 
lean and obese subjects. A) ChREBP mRNA is normalized to IPO8. Each tissue is 369 
compared to its respective lean group. B) Groups are expressed vs lean liver considered 370 
as 1. Data are means± SEM. * p<0.05 vs the respective lean subjects, # p<0.05 vs lean 371 
liver. The number of observations appears in brackets and is the same for both panels. 372 
Figure 2. ChREBP mRNA in floating adipocytes (Ad) and stromal vascular cells 373 
(SVC) from obese patients. SVC from omental (OM) and subcutaneous (SC) adipose 374 
tissue were compared to their respective floating mature adipocytes. Data are mean  375 
SEM, * p< 0.05, n=2/group. 376 
Figure 3. ChREBP mRNA and protein expression in livers from lean and obese 377 
subjects. A) Western-blot of ChREBP protein as compared to ß-actin in liver extracts. 378 
A positive control of HepG2 cells extract (Hep) is included. B) Quantification of 379 
ChREBP levels compared to ß-actin protein expressed as mean  SEM, * p< 0.05, n=4 380 
and n=8 for lean and obese patients, respectively.  381 
Figure 4. Correlation analysis between BMI and ChREBP mRNA expression in 382 
omental adipose tissue. Correlation was determined by Pearson´s correlation 383 
coefficient test (r), n=35 (11 lean and 24 obese). 384 
Figure 5. FASN, AP2, ATGL and ADCY3 mRNA in liver and adipose tissues from 385 
lean/ obese subjects. FASN (A), AP2 (B), ATGL (C) and ADCY3 (D) mRNA 386 
expression are normalized to IPO8. Results are mean  SEM, * p< 0.05 vs its respective 387 
lean group. n appears in brackets. 388 
Figure 6. PPARG, AP2 and ChREBP mRNA and ChREBP protein in omental and 389 
subcutaneous differentiated preadipocytes. Cells were harvested at different days of 390 
differentiation (0, 3, 6 and 12 days). Results are mean  SEM from duplicates of three 391 
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independent experiments from each depot and are normalized to IPO8, * p< 0.05 vs its 392 
respective 0 day, # p< 0.05 vs its respective day3. A representative Western-blot is 393 
shown with ChREBP levels as compared to ß-actin. 394 
 395 
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 Table 1. Biochemical parameters from the obese and lean subjects included in the study. 
 LEAN  
LIVER 
OBESE  
LIVER 
LEAN  
ADIPOSE 
OBESE 
ADIPOSE 
OBESE  
CULTURES 
Range 
Sex (M/F) 2/2 1/8 4/7 5/19 3/5   
Age (years) 44.2 6.4 42.9 3.3 47.6 3.6 44.0 2.3 41.1 5.5  
BMI (kg/m2) 23.6 0.8 47.8 2.2 a 23.0 0.5 49.8  1.5b 47.9 2.1 b  
Glucose (mg/dl) 89.5 5.4 106.1 12.8 86.3 2.6 99.8  5.9b 115.6 8.0 b 60-115 
Cholesterol (mg/dl) 186.3 10.5 172.9 12.5 193.8 6.6 186 .28.9 195.6 12.0 120-240 
Triglycerides (mg/dl) 69.3 7.1 
 
81.9 4.8 65.9 5.6 99.3  9.9b 152.4 17.0b 50-175 
 
Results are means ± SEM. a and b represent a statistical significant difference 
(p<0.05) versus the respective lean group, comparing livers (a) and adipose tissues (b), respectively. 
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